Subscribe To
SAVA / The Crowd Has Wisely Soured on Cassava Sciences Stock
SAVA News
By The Motley Fool
October 31, 2023
1 Big Red Flag to Fear When a Stock Is Down
Stocks often lose much of their value as a result of controversies. Cassava Sciences is facing a raft of serious allegations from numerous parties. more_horizontal
By Seeking Alpha
October 30, 2023
Cassava Sciences: My Bullish Take On Biomarkers And CTAD Data
Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its app more_horizontal
By InvestorPlace
October 16, 2023
SAVA Stock Continues to Plunge on Misconduct Allegations
Big problems appear to be getting worse for Cassava Sciences (NASDAQ: SAVA ). The clinical-stage biotech company is a former favorite among retail inv more_horizontal
By InvestorPlace
October 13, 2023
SAVA Stock Alert: Cassava Sciences Addresses Leaked Report
Cassava Sciences (NASDAQ: SAVA ) stock was hit hard after the market close yesterday following the publication of a Science article that released the more_horizontal
By Proactive Investors
October 13, 2023
Cassava Sciences slumps after leaked report claims 'egregious misconduct' over Alzheimer's drug
Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shar more_horizontal
By Market Watch
October 13, 2023
Cassava shares plummet after investigation accuses researcher of ‘egregious misconduct'
Shares of biotech company Cassava Sciences Inc. were slammed in extended trading Thursday, after the publication Science reported that an investigatio more_horizontal
By Proactive Investors
October 13, 2023
Cassava Sciences slumps after leak claims “egregious misconduct”
Cassava Sciences Inc has denied data manipulation after a probe into conduct over its Alzheimer's drug research was leaked yesterday, sending its shar more_horizontal
By The Motley Fool
October 6, 2023
Why Shares of Cassava Sciences Soared This Week
A rash of insider buying helped buoy the clinical-stage biotech's stock. Cassava said it had completed the enrollment of a phase 3 trial for an Alzhei more_horizontal